Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes

Aims/hypothesis Gastrin has been implicated in islet growth/neogenesis, and proton pump inhibitors (PPIs) have been shown to increase endogenous gastrin levels in animals and humans. Therefore, we investigated the effect of PPIs in a model of type 2 diabetes, Psammomys obesus. Methods P. obesus (mor...

Full description

Saved in:
Bibliographic Details
Published in:Diabetologia 2010-10, Vol.53 (10), p.2220-2223
Main Authors: Bödvarsdóttir, T. B, Hove, K. D, Gotfredsen, C. F, Pridal, L, Vaag, A, Karlsen, A. E, Petersen, J. S
Format: Article
Language:English
Subjects:
2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage
2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use
Analysis of Variance
Animal model
Animals
Antibodies
Beta cell mass
Biological and medical sciences
Blood Glucose - drug effects
Blood Glucose - metabolism
Diabetes
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
Diabetes. Impaired glucose tolerance
Disease Models, Animal
Dose-Response Relationship, Drug
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Enzyme Inhibitors - therapeutic use
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
gastrins
Gastrins - blood
Gerbillinae
Glucose
Glycaemic control
Human Physiology
Hyperglycemia - drug therapy
Immunohistochemistry
Insulin
Insulin - metabolism
Insulin-Secreting Cells - drug effects
Insulin-Secreting Cells - metabolism
Internal Medicine
Lansoprazole
Male
Medical sciences
Medicine
Medicine & Public Health
Metabolic Diseases
noninsulin-dependent diabetes mellitus
Proton pump inhibitor
Proton Pump Inhibitors
Protons
Short Communication
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims/hypothesis Gastrin has been implicated in islet growth/neogenesis, and proton pump inhibitors (PPIs) have been shown to increase endogenous gastrin levels in animals and humans. Therefore, we investigated the effect of PPIs in a model of type 2 diabetes, Psammomys obesus. Methods P. obesus (morning blood glucose [mBG] 16.9 ± 0.6 mmol/l) were treated with vehicle or different doses (1-15 mg/kg) of lansoprazole for 17 days. Results Treatment with lansoprazole resulted in up to ninefold dose-dependent increases in endogenous gastrin levels (p 
ISSN:0012-186X
1432-0428
DOI:10.1007/s00125-010-1825-6